Printer Friendly

Global Soft Tissue Repair Market to Reach USD 21.319bn by 2023, Research and Markets Forecasts.

M2 PHARMA-April 26, 2017-Global Soft Tissue Repair Market to Reach USD 21.319bn by 2023, Research and Markets Forecasts


- The soft tissue repair global market is expected to grow at high single digit CAGR to reach USD 21,319.7m by 2023, according to a new report from Dublin-based Research and Markets.

Factors driving the soft tissue repair market include, increase in aging population, increase in medical procedures and sports injuries along with technology advancements and growing investment potential in emerging markets are contributing to the growth of soft tissue repair global market.

A lack of awareness, limited reimbursements and high cost of procedures are hampering the market growth.

Advancement of technology with its wide application areas shows that soft tissue repair market has vast opportunities in the coming years.

Based on application, the soft tissue repair products are segmented into hernia repair, dental reconstruction, vaginal sling procedure, skin repair, breast reconstruction, orthopedic (dural repair and sports medicine), cardiac repair (transcatheter aortic valve replacement, mechanical heart valve replacement, biological heart valve replacement, annuloplasty ring, MitraClip, occluders, stent grafts and cardiac tissue patches).

Key market trends include an increased incidence of soft tissue injuries, a rise in the ageing population, technological advancements, an increase in investments and growth in emerging markets.

((Comments on this story may be sent to

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Apr 26, 2017
Previous Article:Surgical Sutures Market to Reach USD 4.40bn by 2021, Research and Markets Forecasts.
Next Article:Sandison Named Chief Medical Officer at Cidara Therapeutics.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters